» Articles » PMID: 38005401

Joining Forces: The Combined Application of Therapeutic Viruses and Nanomaterials in Cancer Therapy

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Nov 25
PMID 38005401
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer, on a global scale, presents a monumental challenge to our healthcare systems, posing a significant threat to human health. Despite the considerable progress we have made in the diagnosis and treatment of cancer, realizing precision cancer therapy, reducing side effects, and enhancing efficacy remain daunting tasks. Fortunately, the emergence of therapeutic viruses and nanomaterials provides new possibilities for tackling these issues. Therapeutic viruses possess the ability to accurately locate and attack tumor cells, while nanomaterials serve as efficient drug carriers, delivering medication precisely to tumor tissues. The synergy of these two elements has led to a novel approach to cancer treatment-the combination of therapeutic viruses and nanomaterials. This advantageous combination has overcome the limitations associated with the side effects of oncolytic viruses and the insufficient tumoricidal capacity of nanomedicines, enabling the oncolytic viruses to more effectively breach the tumor's immune barrier. It focuses on the lesion site and even allows for real-time monitoring of the distribution of therapeutic viruses and drug release, achieving a synergistic effect. This article comprehensively explores the application of therapeutic viruses and nanomaterials in tumor treatment, dissecting their working mechanisms, and integrating the latest scientific advancements to predict future development trends. This approach, which combines viral therapy with the application of nanomaterials, represents an innovative and more effective treatment strategy, offering new perspectives in the field of tumor therapy.

Citing Articles

Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells.

Abdessalem M, Adham S Oncol Res. 2024; 33(1):27-44.

PMID: 39735681 PMC: 11671623. DOI: 10.32604/or.2024.056955.

References
1.
Kinoshita T, Ujiie H, Chen J, Ding L, Chan H, Gregor A . Evaluation of Novel Imaging Devices for Nanoparticle-Mediated Fluorescence-Guided Lung Tumor Therapy. Ann Thorac Surg. 2019; 107(6):1613-1620. DOI: 10.1016/j.athoracsur.2019.01.008. View

2.
Davodabadi F, Sarhadi M, Arabpour J, Sargazi S, Rahdar A, Diez-Pascual A . Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. J Control Release. 2022; 349:844-875. DOI: 10.1016/j.jconrel.2022.07.036. View

3.
Harrington K, Freeman D, Kelly B, Harper J, Soria J . Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019; 18(9):689-706. DOI: 10.1038/s41573-019-0029-0. View

4.
Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

5.
Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G . Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. Front Cell Dev Biol. 2016; 4:83. PMC: 4992732. DOI: 10.3389/fcell.2016.00083. View